Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217.

Autor: Kovacech, Branislav1 (AUTHOR) kovacech@axon-neuroscience.eu, Cullen, Nicholas C.2 (AUTHOR), Novak, Petr1 (AUTHOR), Hanes, Jozef1 (AUTHOR), Kontsekova, Eva3 (AUTHOR), Katina, Stanislav4 (AUTHOR), Parrak, Vojtech1 (AUTHOR), Fresser, Michal5 (AUTHOR), Vanbrabant, Jeroen6 (AUTHOR), Feldman, Howard H.7 (AUTHOR), Winblad, Bengt8,9 (AUTHOR), Stoops, Erik6 (AUTHOR), Vanmechelen, Eugeen6 (AUTHOR), Zilka, Norbert1 (AUTHOR) zilka@axon-neuroscience.eu
Zdroj: Alzheimer's Research & Therapy. 11/23/2024, Vol. 16 Issue 1, p1-14. 14p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje